Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma
2011; Elsevier BV; Volume: 23; Issue: 7 Linguagem: Inglês
10.1093/annonc/mdr535
ISSN1569-8041
AutoresPaul Hofman, Marius Ilié, Véronique Hofman, S. Roux, A. Valent, Alain Bernheim, Marco Alifano, François Leroy-Ladurie, F. Vaylet, Isabelle Rouquette, Pierre Validire, Michèle Beau‐Faller, Ludovic Lacroix, Jean‐Charles Soria, P Fouret,
Tópico(s)Lung Cancer Diagnosis and Treatment
ResumoBackgroundImmunohistochemistry has been proposed as a specific and sensitive method to identify EGFR mutations or ALK rearrangements in lung tumours.Patients and methodsWe assessed EGFR and KRAS by direct sequencing in 154 patients with lung adenocarcinoma. ALK rearrangements were assayed by FISH and RT-PCR. Immunohistochemistry was carried out and evaluated closely following published methods using recommended monoclonal rabbit or mouse antibodies.ResultsThirteen of 36 exon 19 EGFR-mutated tumours (36%)—including 12 of 22 with p.Glu746_Ala750del (55%)—were positive with the 6B6 antibody that was raised against p.Glu746_Ala750del. One hundred eleven of 114 EGFR exon 19 wild-type tumours (97%) were negative with 6B6. Four of 21 exon 21 EGFR-mutated tumours (19%)—including 4 of 17 with p.Leu858Arg (24%)—were positive with the 43B2 antibody that was raised against p.Leu858Arg. One hundred twenty-two of 124 (98%) EGFR exon 21 wild-type tumours were negative with 43B2. Two of four ALK rearrangements—including two of three with ELM4-ALK fusion transcripts—were identified with the 5A4 antibody. Eleven of 13 tumours without ALK rearrangement (85%) were negative with 5A4.ConclusionsImmunohistochemistry is a specific means for identification of EGFR mutations and ALK rearrangements. It suffers, however, from poor sensitivity.
Referência(s)